AJR Am J Roentgenol

1. ABREU-GOMEZ J
   Artificial Intelligence-Assisted MRI Interpretation in Prostate Cancer: Supporting Confidence and Reducing Variability.
   AJR Am J Roentgenol. 2025 Aug 6. doi: 10.2214/AJR.25.33622.
   

   >> Share

   
   

   
   Anticancer Res

2. HATTORI A, Seki T, Kato K, Virgona N, et al
   NK Cells Can Target Castration-resistant Prostate Cancer Stem Cells With the Involvement of Degranulation Pathway.
   Anticancer Res. 2025;45:3197-3207.
   

   >> Share

   
   
3. BABU YSR, Venkatachalam KV
   Methionine Deprivation-induced Cancer Cell Death and Methylation Changes in Key Genes and Gene Promoters of Prostate Cancer Cell Lines.
   Anticancer Res. 2025;45:3209-3219.
   

   >> Share

   
   

   
   BJU Int

4. OLIVIER J, Vertosick E, Delobel L, Bommelaere T, et al
   Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.
   BJU Int. 2025 Aug 7. doi: 10.1111/bju.16884.
   

   >> Share

   
   
5. SANAPALA K, Mehta R, Sah R
   Comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.
   BJU Int. 2025 Aug 2. doi: 10.1111/bju.16868.
   

   >> Share

   
   

   
   BMC Cancer

6. AHAMED Y, Hossain M, Baral S, Al-Raiyan AU, et al
   The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.
   BMC Cancer. 2025;25:1264.
   

   >> Share

   
   

   
   BMC Urol

7. DINC SC, Ucgul AN, Bora H, Senturk E, et al
   The dosimetric impacts of ct-based deep learning autocontouring algorithm for prostate cancer radiotherapy planning dosimetric accuracy of DirectORGANS.
   BMC Urol. 2025;25:190.
   

   >> Share

   
   
8. SUN J, Song Y, Tan Y, Ma L, et al
   Predictive value of inflammatory marker PLR in prostate cancer.
   BMC Urol. 2025;25:188.
   

   >> Share

   
   

   
   Cancer

9. TSUNG I, Yentz SE, Reichert ZR
   Controversies in metastatic hormone-sensitive prostate cancer.
   Cancer. 2025;131:e70030.
   

   >> Share

   
   
10. NORIEGA ESQUIVES BS, Manoharan A, Penedo FJ, Dee EC, et al
    Factors associated with prostate cancer screening among Hispanic men: Results from the Hispanic Community Health Study/Study of Latinos.
    Cancer. 2025;131:e70029.
    

    >> Share

    
    
11. NIERENGARTEN MB
    Superior prostate cancer detection with LATP versus TRUS.
    Cancer. 2025;131:e35958.
    

    >> Share

    
    

    
    Cancer Res

12. CORDOVA RA, Elbanna M, Rupert C, Orsi SA, et al
    Caloric Restriction Enhances the Efficacy of Anti-Androgen Therapy in Prostate Cancer by Inhibiting Androgen Receptor Translation.
    Cancer Res. 2025 Aug 8. doi: 10.1158/0008-5472.CAN-24-1986.
    

    >> Share

    
    
13. MA S, Ge Y, Lu Z, Zhang J, et al
    Integrated Omics and Multi-Cohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer.
    Cancer Res. 2025 Aug 4. doi: 10.1158/0008-5472.CAN-24-5018.
    

    >> Share

    
    

    
    Eur Radiol

14. JOHNSON PM, Tong A, Ginocchio L, Del Hoyo JL, et al
    External evaluation of an open-source deep learning model for prostate cancer detection on bi-parametric MRI.
    Eur Radiol. 2025 Aug 3. doi: 10.1007/s00330-025-11865.
    

    >> Share

    
    
15. KEIVANY MR, Zare H
    Letter to the Editor: MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11896.
    

    >> Share

    
    
16. NAVES AA, de Lion Gouvea G, Machado CVB, Colli LM, et al
    Reply to the Letter to the Editor: MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11897.
    

    >> Share

    
    
17. THORLEY N, Parry T, Giganti F, Kopcke D, et al
    Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study).
    Eur Radiol. 2025 Aug 6. doi: 10.1007/s00330-025-11837.
    

    >> Share

    
    

    
    Eur Urol

18. SHERRY AD, Siddiqui BA, Haymaker C, Fellman BM, et al
    Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.
    Eur Urol. 2025 Jul 31:S0302-2838(25)00396-3. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    
19. HALABI S, Guo S, Luo B, Yu C, et al
    Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.
    Eur Urol. 2025 Aug 6:S0302-2838(25)00407-5. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    Int J Oncol

20. LONG Z, Chang Y, Zhu K, Chen Z, et al
    Cuproptosis in prostate cancer: Molecular mechanisms, prognostic biomarkers and therapeutic frontiers of cuproptosis?related genes (Review).
    Int J Oncol. 2025;67:77.
    

    >> Share

    
    

    
    Int J Urol

21. TOHI Y, Kato T, Fujiwara K, Harada S, et al
    Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection.
    Int J Urol. 2025 Aug 3. doi: 10.1111/iju.70193.
    

    >> Share

    
    
22. SOMOTO T, Utsumi T, Ishitsuka N, Noro T, et al
    Clinical Predictors of Fluoroquinolone-Resistant Escherichia coli in Transrectal Ultrasound-Guided Prostate Biopsy: Insights for Tailored Prophylaxis.
    Int J Urol. 2025;32:982-989.
    

    >> Share

    
    

    
    J Clin Oncol

23. MENNE GURICOVA K, Draulans C, Pos FJ, Kerkmeijer LGW, et al
    Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial.
    J Clin Oncol. 2025 Aug 4:JCO2500274. doi: 10.1200/JCO-25-00274.
    

    >> Share

    
    

    
    J Nucl Med

24. GRKOVSKI M, Krebs SS, O'Donoghue JA, Kuten J, et al
    Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.
    J Nucl Med. 2025 Aug 7:jnumed.125.270170. doi: 10.2967/jnumed.125.270170.
    

    >> Share

    
    
25. KASHYAP R, Buteau JP, Bressel M, Eifer M, et al
    Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.
    J Nucl Med. 2025 Jul 3:jnumed.125.269640. doi: 10.2967/jnumed.125.269640.
    

    >> Share

    
    
26. IAGARU A, Suarez JF, Behr S, Aggarwal R, et al
    Imaging Efficacy of [(18)F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
    J Nucl Med. 2025 Jun 5:jnumed.124.269007. doi: 10.2967/jnumed.124.269007.
    

    >> Share

    
    

    
    Lancet Oncol

27. EMMETT L, Papa N, Subramaniam S, Crumbaker M, et al
    Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2025 Jul 30:S1470-2045(25)00339.
    

    >> Share

    
    

    
    N Engl J Med

28. 
    Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2025 Aug 1. doi: 10.1056/NEJMx250003.
    

    >> Share

    
    

    
    Nat Rev Urol

29. NI HM, Kouzy R, Sabbagh A, Rooney MK, et al
    The state of the art in artificial intelligence and digital pathology in prostate cancer.
    Nat Rev Urol. 2025 Aug 4. doi: 10.1038/s41585-025-01070.
    

    >> Share

    
    

    
    Oncogene

30. SANCHIS P, Sabater A, Lechuga J, Rada J, et al
    PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression.
    Oncogene. 2025 Aug 2. doi: 10.1038/s41388-025-03511.
    

    >> Share

    
    
31. HAO JL, He JQ, Hu H, Zhu ZH, et al
    TLL1 knockdown attenuates prostate cancer progression by enhancing antitumor immunity.
    Oncogene. 2025 Aug 4. doi: 10.1038/s41388-025-03517.
    

    >> Share

    
    
32. ANDRIEU C, Taieb D, Baylot V, Ettinger S, et al
    Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Oncogene. 2025 Aug 7. doi: 10.1038/s41388-025-03531.
    

    >> Share

    
    

    
    PLoS Comput Biol

33. GOLZARYAN A, Souri M, Kashkooli FM, Rahmim A, et al
    Multi-scale computational modeling towards efficacy in radiopharmaceutical therapies while minimizing side effects: Modeling of amino acid infusion.
    PLoS Comput Biol. 2025;21:e1013247.
    

    >> Share

    
    

    
    Urol Int

34. ELLEISY M, Zettl H, Drager DL, Hakenberg OW, et al
    The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A Single-Center Experience.
    Urol Int. 2025;109:361-371.
    

    >> Share

    
    

    
    Urology

35. MICHAEL JA, Greenberg DR, Ascha M, Gonzales-Alabastro CD, et al
    Prostate Specific Antigen Testing and Prostate Cancer Diagnosis Rates Among Transgender and Nonbinary Patients: Retrospective Review of a Single-Institution Experience.
    Urology. 2025 Jul 31:S0090-4295(25)00735-6. doi: 10.1016/j.urology.2025.
    

    >> Share

    
    
36. KARWACKI J, Wojdylo L, Klasen K, Dlubak A, et al
    Reply to Letter to the Editor on "Revisiting the Role of Lymphovascular Invasion in Prostate Cancer: A Narrative Review".
    Urology. 2025 Aug 1:S0090-4295(25)00750-2. doi: 10.1016/j.urology.2025.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share